EA200702435A1 - Иммуномодулирующие гетероциклические соединения - Google Patents

Иммуномодулирующие гетероциклические соединения

Info

Publication number
EA200702435A1
EA200702435A1 EA200702435A EA200702435A EA200702435A1 EA 200702435 A1 EA200702435 A1 EA 200702435A1 EA 200702435 A EA200702435 A EA 200702435A EA 200702435 A EA200702435 A EA 200702435A EA 200702435 A1 EA200702435 A1 EA 200702435A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heterocyclic compounds
immunomodulating
immunomodulating heterocyclic
solvate
hydrate
Prior art date
Application number
EA200702435A
Other languages
English (en)
Other versions
EA014080B1 (ru
Inventor
Йен Ричард Мэтьюс
Original Assignee
Эвидекс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305876A external-priority patent/GB0305876D0/en
Priority claimed from GB0319429A external-priority patent/GB0319429D0/en
Application filed by Эвидекс Лимитед filed Critical Эвидекс Лимитед
Publication of EA200702435A1 publication Critical patent/EA200702435A1/ru
Publication of EA014080B1 publication Critical patent/EA014080B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Соединения формулы (I) являются ингибиторами CD80 и применимы в иммуномодулирующей терапии, где Rи R, независимо, обозначают Н; F; Cl; Br; -NO, -CN; C-Салкил, необязательно замещённый F или Cl; или C-Салкокси, необязательно замещённый F; Rобозначает карбоксильную кислотную группу (-СООН) или её эфир, или -C(=O)NRR, -NRC(=O)R, -NRC(=O)OR, -NHC(=O)NRRили -NHC(=S)NRR, где Rобозначает Н или радикал формулы -(Alk)-Q, где m обозначает 0 или 1, Alk обозначает необязательно замещённый двухвалентный линейный или разветвлённый C-Cалкиленовый, или C-Салкениленовый, или C-Салкиниленовый радикал, или двухвалентный С-Cкарбоциклический радикал, любой из этих радикалов может содержать одну или более -О-, -S- или - N(R)- связей, где Rобозначает Н или C-Cалкил, С-Cалкенил, С-Cалкинил, или С-Сциклоалкил, и Q обозначает Н; -NRR, где Rи R, независимо, обозначают Н; C-Cалкил; С-Cалкенил; С-Cалкинил; С-Сциклоалкил; сложноэфирную группу; необязательно замещённую карбоциклическую или гетероциклическую группу; или Rи Rвместе с атомом азота, с которым они связаны, образуют цикл, который, необязательно, является замещённым; и Rобозначает Н или C-Салкил, или Rи Rвместе с атомом или атомами, с которым(и) они связаны, образуют необязательно замещённый моноциклический гетероцикл, содержащий 5, 6 или 7 атомов в цикле; и Х обозначает связь или двухвалентный радикал формулы -(Z)-(Alk)- или -(Alk)-(Z)-, где Z обозначает -О-, -S- или -NH-, Alk имеет значение по определению для R, а n обозначает 0 или 1.
EA200702435A 2003-03-14 2004-03-10 Иммуномодулирующие гетероциклические соединения EA014080B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305876A GB0305876D0 (en) 2003-03-14 2003-03-14 Immuno inhibitory heterocyclic compounds
GB0319429A GB0319429D0 (en) 2003-08-19 2003-08-19 Immuno Inhibitory Heterocyclic compounds

Publications (2)

Publication Number Publication Date
EA200702435A1 true EA200702435A1 (ru) 2008-06-30
EA014080B1 EA014080B1 (ru) 2010-08-30

Family

ID=32992598

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200702435A EA014080B1 (ru) 2003-03-14 2004-03-10 Иммуномодулирующие гетероциклические соединения
EA200501370A EA009680B1 (ru) 2003-03-14 2004-03-10 Иммуномодулирующие гетероциклические соединения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200501370A EA009680B1 (ru) 2003-03-14 2004-03-10 Иммуномодулирующие гетероциклические соединения

Country Status (20)

Country Link
US (3) US7276505B2 (ru)
EP (2) EP2284172A1 (ru)
JP (1) JP4892338B2 (ru)
KR (1) KR101133959B1 (ru)
AT (1) ATE489388T1 (ru)
BR (1) BRPI0408365B8 (ru)
CA (1) CA2519063C (ru)
DE (1) DE602004030225D1 (ru)
DK (1) DK1603917T3 (ru)
EA (2) EA014080B1 (ru)
EC (1) ECSP056104A (ru)
HK (1) HK1090921A1 (ru)
IL (1) IL170389A (ru)
MX (1) MXPA05009667A (ru)
NO (1) NO332136B1 (ru)
NZ (1) NZ541973A (ru)
PL (2) PL383655A1 (ru)
PT (1) PT1603917E (ru)
SI (1) SI1603917T1 (ru)
WO (1) WO2004081011A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2284172A1 (en) * 2003-03-14 2011-02-16 MediGene Ltd. Immunomodulating heterocyclic compounds
GB0325644D0 (en) * 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DK1776366T3 (da) * 2004-08-09 2009-02-16 Medigene Ltd Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer
WO2007017289A2 (en) * 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
AU2007227681A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CN101432261A (zh) 2006-05-19 2009-05-13 惠氏公司 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺
EP2047848A4 (en) * 2006-07-05 2010-06-09 Univ Tokyo METHOD FOR THE TREATMENT OF GENETIC DISEASES BASED ON A NONSENSE MUTATION
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
AR067549A1 (es) 2007-07-16 2009-10-14 Wyeth Corp Compuesto de oxazol,tiazol e imidazol, composicion farmaceutica que lo comprende , proceso para la preparacion del compuesto , uso del compuesto y metodos para la inhibicion del receptor h3 y para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina -3 (h3
EP2020404A1 (en) * 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2676666A1 (en) 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
AU2015315177A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
WO2018110669A1 (en) 2016-12-15 2018-06-21 Ono Pharmaceutical Co., Ltd. Activator of trek (twik related k+ channels) channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629412A (en) 1946-12-24 1949-09-20 Geigy Ag J R Manufacture of metallisable monoazo dyestuffs of the pyrazolone series
US3576637A (en) * 1967-04-20 1971-04-27 Konishiroku Photo Ind Lith-type of emulsion containing pyrozolone
JPS61161285A (ja) * 1984-12-28 1986-07-21 ルセル−ユクラフ ピラゾロ〔4,3−c〕シンノリン−3−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物
US4591589A (en) * 1985-01-16 1986-05-27 Roussel Uclaf 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
DE3626221A1 (de) 1986-08-02 1988-02-04 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder
US4906644A (en) 1986-11-20 1990-03-06 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
AR006520A1 (es) 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
WO2003004485A1 (en) 2001-07-05 2003-01-16 Takeda Chemical Industries, Ltd. Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP1562944B1 (en) 2002-11-22 2007-02-14 Active Biotech AB Pyrazoloquinolines with immunomodulating activity
ATE425164T1 (de) 2002-12-16 2009-03-15 Active Biotech Ab Tetrazyklische immunmodulierende verbindungen
EP2284172A1 (en) * 2003-03-14 2011-02-16 MediGene Ltd. Immunomodulating heterocyclic compounds
GB0325644D0 (en) * 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DK1776366T3 (da) * 2004-08-09 2009-02-16 Medigene Ltd Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer
US20060221590A1 (en) * 2005-03-31 2006-10-05 Edoardo Campini System and method for Advanced Mezzanine Card connection
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition

Also Published As

Publication number Publication date
WO2004081011A1 (en) 2004-09-23
EA009680B1 (ru) 2008-02-28
BRPI0408365B1 (pt) 2018-11-21
PT1603917E (pt) 2011-02-04
KR20050121681A (ko) 2005-12-27
PL1603917T3 (pl) 2011-12-30
DK1603917T3 (da) 2011-02-28
PL383655A1 (pl) 2008-04-14
EP2284172A1 (en) 2011-02-16
EA200501370A1 (ru) 2006-08-25
US7276505B2 (en) 2007-10-02
NZ541973A (en) 2009-06-26
ECSP056104A (es) 2006-03-01
DE602004030225D1 (de) 2011-01-05
CA2519063A1 (en) 2004-09-23
SI1603917T1 (sl) 2011-04-29
EP1603917A1 (en) 2005-12-14
CA2519063C (en) 2011-05-10
JP4892338B2 (ja) 2012-03-07
NO20054710L (no) 2005-12-13
BRPI0408365A (pt) 2006-03-21
JP2006520372A (ja) 2006-09-07
IL170389A (en) 2013-08-29
AU2004220310A1 (en) 2004-09-23
MXPA05009667A (es) 2006-01-27
KR101133959B1 (ko) 2012-04-09
US8309552B2 (en) 2012-11-13
ATE489388T1 (de) 2010-12-15
EA014080B1 (ru) 2010-08-30
EP1603917B1 (en) 2010-11-24
NO20054710D0 (no) 2005-10-13
US20080045527A1 (en) 2008-02-21
BRPI0408365B8 (pt) 2021-05-25
US20090312334A1 (en) 2009-12-17
HK1090921A1 (en) 2007-01-05
US7598247B2 (en) 2009-10-06
US20070021428A1 (en) 2007-01-25
NO332136B1 (no) 2012-07-02

Similar Documents

Publication Publication Date Title
NO20054710L (no) Immunmodulerende heterosykliske forbindelser
NL300927I9 (nl) Tivozanib of een zout, solvaat of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
ATE377420T1 (de) Phenylalkansäure- und phenyloxyalkansäure- derivate als hppar aktivatore
GB2392154B (en) Protein Kinase Inhibitors
GB2398781B (en) Kinase inhibitors
SI1585739T1 (sl) Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
EA200801381A1 (ru) Производные пиримидина
NO20054669L (no) Substituerte kinobenzoxazinanaloger
DE60319080D1 (de) Phenyloxyalkansäure-derivate als hppar aktivatore
MXPA05011276A (es) Derivado heterociclico de cinco miembros.
GB0215392D0 (en) Chemical compounds
HK1086835A1 (en) N-[({'4-substituted piperazine-1-y}sulfonylmethyl)alkyl]-n-hxdroxyformamide compounds as metallopro teinase inhibitors
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen
TW200518748A (en) Chemical compounds
WO2004103305A3 (en) Spiropyrazole compound
DOP2002000354A (es) Compuestos farmaceuticamente activos.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ RU